As of November 6, 2026, Spyre Therapeutics, Inc. is a publicly traded company (Nasdaq: SYRE). The largest holder reporting an active stake on Schedule 13D is Fairmount Funds Management LLC, at 9.99%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Passive holders reporting on Schedule 13G include BlackRock (6.6%), Paradigm BioCapital Advisors LP (5.1%) (Schedule 13D/A, October 9, 2026).
Is this your company?
About to sign with, pay or invest in Spyre Therapeutics, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Spyre Therapeutics, Inc. a real, registered company?
- Spyre Therapeutics, Inc. files with the SEC under CIK 1636282 (its SEC filings).
- Its shares are listed under the ticker SYRE on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Waltham, Massachusetts, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Spyre Therapeutics, Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Fairmount Funds Management LLC (filed 2026-10-09).
Who are Spyre Therapeutics, Inc.'s owners and officers?
Spyre Therapeutics, Inc.: incorporated in Delaware; business address in Waltham, Massachusetts; industry Pharmaceutical Preparations (Schedule 13D/A, 2026-10-09).
Officers and directors, each with the role and the filing that names them:
- : Executive Officer, Director (Form D, 2023-12-27)
- : Executive Officer (Form D, 2023-12-27)
- : Executive Officer (Form D, 2023-12-27)
- : Director (Form D, 2023-12-27)
- : Director (Form D, 2023-12-27)
- : Director (Form D, 2023-12-27)
- : Director (Form D, 2023-12-27)
- : Director (Form D, 2023-12-27)
- : Director (Form D, 2023-12-27)
- : Director (Form D, 2023-12-27)
| Report | Holder | Share |
|---|---|---|
| Schedule 13D/A, 2026-10-09 | Fairmount Funds Management LLC | 9.99% |
| Schedule 13G, 2026-10-01 | Paradigm Biocapital Advisors LP | 5.1% |
| Schedule 13G/A, 2026-08-14 | Rtw Investments, LP | 4.8% |
| Schedule 13G/A, 2026-08-14 | Perceptive Advisors LLC | 4.9% |
| Schedule 13D/A, 2026-06-23 | Fairmount Funds Management LLC | 9.99% |
| Schedule 13G, 2026-04-22 | Perceptive Advisors LLC | 5% |
| Schedule 13D/A, 2026-04-20 | Fairmount Funds Management LLC | 9.99% |
| Schedule 13G/A, 2026-03-27 | The Vanguard Group | 0% |
| Schedule 13G/A, 2026-02-17 | Tang Capital Management, LLC | 2.4% |
| Schedule 13D/A, 2025-10-17 | Fairmount Funds Management LLC | 9.99% |
| Schedule 13G, 2025-07-29 | The Vanguard Group | 5.08% |
| Schedule 13G/A, 2025-07-16 | Blackrock, Inc. | 6.6% |
Questions about who owns Spyre Therapeutics, Inc.
Who owns Spyre Therapeutics, Inc.?
On this page, 3 holders' latest ownership filings report 5% or more of Spyre Therapeutics, Inc.: Fairmount Funds Management LLC (9.99%, Schedule 13D/A, filed 2026-10-09), Blackrock, Inc. (6.6%, Schedule 13G/A, filed 2025-07-16) and Paradigm Biocapital Advisors LP (5.1%, Schedule 13G, filed 2026-10-01).
Who are the largest shareholders of Spyre Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Spyre Therapeutics, Inc. on this page are Fairmount Funds Management LLC (9.99%), Blackrock, Inc. (6.6%) and Paradigm Biocapital Advisors LP (5.1%).
When did Fairmount Funds Management LLC buy into Spyre Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Fairmount Funds Management LLC on this page is the Schedule 13D/A, filed 2025-10-17, reporting 9.99%; its latest, Schedule 13D/A filed 2026-10-09, reports 9.99%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Spyre Therapeutics, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Spyre Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Spyre Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
17 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Spyre Therapeutics, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- Fairmount Healthcare Fund II L.P., a director: 812,076 shares (0.86% of shares outstanding), held indirectly through By Fairmount Healthcare Fund II L.P., on a joint filing (Form 4, 2026-06-23).
- , a director: 812,076 shares (0.86% of shares outstanding), held indirectly through By Fairmount Healthcare Fund II L.P., on a joint filing (Form 4, 2026-06-23).
- Fairmount Funds Management LLC, a director: 812,076 shares (0.86% of shares outstanding), held indirectly through By Fairmount Healthcare Fund II L.P., on a joint filing (Form 4, 2026-06-23).
- , a director: 812,076 shares (0.86% of shares outstanding), held indirectly through By Fairmount Healthcare Fund II L.P., on a joint filing (Form 4, 2026-06-23).
- , the chief executive and a director: 537,540 shares (0.57% of shares outstanding) (Form 4, 2026-10-02).
Shares outstanding: 94,969,184 as of 2026-10-27, from the company's latest SEC cover page.
How much has Spyre Therapeutics, Inc. raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2023-12-27 | $180M | $180M |
| Form D, 2023-07-06 | $210M | $210M |
Keep reading
More on Spyre Therapeutics, Inc. and the records around it.
Spyre Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
Companies that share a holder
- Fairmount Funds Management LLC also filed stake reports on 13 other companies: Alaunos Therapeutics, Inc. (Oct 2026), Korsana Biosciences, Inc. (Sep 2026), Apogee Therapeutics, Inc. (Sep 2026)
- Paradigm BioCapital Advisors LP also filed stake reports on 22 other companies: Obsidian Therapeutics, Inc. (Oct 2026), Tyra Biosciences, Inc. (Sep 2026), Arcellx, Inc. (Aug 2026)
- TANG CAPITAL MANAGEMENT, LLC also filed stake reports on 33 other companies: EyePoint, Inc. (Oct 2026), Skye Bioscience, Inc. (Oct 2026), Nano Dimension Ltd. (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/spyre-therapeutics